Bioconjugates
Antibody-drug conjugates might revolutionize the treatment of cancer and various other diseases. However, there are some challenges to overcome in their handling, including controlled freezing – find out more in this article!
Johannes Kirchmair
October 13, 2022
Articles by Biopharmaceutical Products:
Articles by Manufacturing Processes:
E-Book
A multinational CDMO (contract development and manufacturing organization) with USD 5 billion turnover develops and manufactures pharmaceuticals that are outsourced from biotechnology companies. Based on requirements the CDMO takes full responsibility of manufacturing of drug substance, cell & gene therapies and more within the contraced period of time.
E-Book
Scalability around freezing means the ability to guarantee constant freezing kinetics on proteins (biopharmaceutical molecules) in all scales, filling volumes and loading scenarios. This guide covers how to achieve scalable freezing & thawing of biopharmaceuticals by showing What is scalability? Setup for controlled icefront growth speed Scalability results Outcomes
E-Book
This guide for bioconjugate manufacturing with regards to fluid and cold chain management addresses challenges such as: protection against ADC toxicity, accuracy in fluid management, maintaining ADC stability after freeze-thaw cycles, transition from lab to commercialization, and cost considerations of equipment.
